ADAM10 Specific Neutra™ Antibody Products

ADAM metallopeptidase structural domain 10, also known as ADAM10, is a type I transmembrane glycoprotein belonging to the ADAM (a disintegrin and metalloproteinase) family of proteins, which is broadly expressed in several tissues, including the brain, heart, and immune system. ADAM10 plays a crucial role as a sheddase by cleaving cell surface proteins to release their extracellular domains. This enzyme can cleave a wide range of substrates such as growth factors, cytokines, and adhesion molecules, revealing its versatility in regulating cellular processes. Moreover, ADAM10 is essential for the protein hydrolysis process of amyloid precursor protein (APP). Cleavage of APP by ADAM10 results in the formation of neuroprotective soluble APP α (sAPPα). ADAM10 has been identified as a promising therapeutic target for some disorders, including cancer, chronic inflammatory diseases, and Alzheimer's disease.

Its Gene ID: 102, UniProtKB ID: O14672, and OMIM ID: 602192.

Fig.1 The structure and physiopathology of ADAMs.¹

ADAM10 in Cancer

ADAM10 is a major sheddase for Notch, CD44, and L1, which are closely associated with tumorigenesis and progression. The binding of Notch to its ligand initiates ADAM10-mediated ligand-dependent shedding of Notch extracellular structural domains, which triggers the subsequent γ-secretase-mediated release of Notch intracellular structural domains. Enhanced Notch signaling induces the oncogenic transformation of normal cells and promotes the progression of hematological and solid cancers. By inhibiting ADAM10-mediated Notch cleavage, the development of T-cell acute lymphoblastic leukemia (T-ALL), breast, ovarian, and gastrointestinal cancers can be inhibited. ADAM10 also mediates CD44 shedding and subsequently enhances CD44-dependent tumor cell migration (e.g., lung cancer and glioblastoma) via epidermal growth factor receptor (EGFR/ErbB1) signaling. In addition, ADAM10 can regulate glioblastoma cell migration and invasion by shedding N-cadherin and L1.

ADAM10 Antibody for Cancer Therapy

Small molecule inhibitors usually act by interacting with multiple targets. This may lead to a range of non-specific effects, thereby increasing side effects. In contrast, Anti-ADAM10 monoclonal antibodies (mAbs) can more precisely recognize and bind to a specific conformation of ADAM10 substrate structural domains dependent on CxxC bonding, resulting in higher target specificity. Anti-ADAM10 mAb can distinguish tumor cells from normal or non-malignant cells, preferentially targeting ADAM10 in tumors to inhibit Notch signaling and tumor growth, especially regeneration after chemotherapy.

Creative Biolabs offers high-quality anti-ADAM10 mAb products. Our antibody undergoes a rigorous recombinant expression and purification process to ensure its stability and activity, which is suitable for a wide range of assays such as IP, WB, inhibition and functional assays.

REFERENCE

1. Kato, Takashi, Man Hagiyama, and Akihiko Ito. "Renal ADAM10 and 17: their physiological and medical meanings." Frontiers in cell and developmental biology 6 (2018): 153. Distributed under open access license CC BY 4.0, without modification.